Clinical Trial for Women with LAM now enrolling at Brigham and Women's Hospital

Brigham and Women's Hospital in Boston, MA is looking for women with lymphangioleiomyomatosis (LAM) to participate in a new research study. This study is to test the safety and effectiveness of Celecoxib. Celecoxib is approved by the FDA for other diseases; however it is not approved to treat LAM. This means that the use of Celecoxib in LAM is considered experimental.

You may be eligible for this study if you are a woman diagnosed with LAM, are over 18 to 69 years of age and are not pregnant.

Possible risks of the study include an upset stomach, headaches, liver and kidney dysfunction.

Participation in the trial would require 4 visits over a period of 6 months. You will receive 6 months of study drug. Study visits will include physical exam, blood and urine analysis, X-ray, MRIs (magnetic resonance imaging), and breathing tests. Participants will also keep a home diary.

Please contact Souheil El-Chemaly, MD by email sel-chemaly@partners.org if you are interested in hearing more about this clinical trial or if you would like to schedule an appointment for screening.